By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

RegeneRx Biopharmaceuticals, Inc. 

3 Bethesda Metro Center, Suite 630

Bethesda  Maryland  20814  U.S.A.
Phone: 301-280-1992 Fax: 301-280-1996


SEARCH JOBS








Company News
Complete Data From RegeneRx Biopharmaceuticals, Inc. (RGRX) Phase II Dry Eye Trial Published In Current Issue Of Clinical Ophthalmology 5/22/2015 6:47:17 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Researchers Report That Long-Term Administration Of Thymosin B4 In A Diabetic Animal Model Prevents Progression Of Peripheral Neuropathy And Restores Sciatic Nerve Function 5/8/2015 11:25:22 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Researchers Report That Thymosin B4 Has A Major Role In Dermal Burn Wound Healing 5/4/2015 9:04:42 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice of Allowance For U.S. Patent For Healing And Reversing Heart And Coronary Vessel Damage After A Heart Attack With TB4 4/23/2015 11:05:05 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX)'s RGN-259 Meets Key Efficacy Objectives In Phase II Clinical Trial In Patients With Severe Dry Eye Reported In Current Issue Of Cornea 4/1/2015 7:00:43 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Israeli Patent Acceptance Notice For The Use Of TB4 To Prevent Tissue Damage Associated With Heart Attack And Stroke Treatments 3/26/2015 11:14:09 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Initial Payment For RGN-259 U.S. License To ReGenTree Joint Venture 3/25/2015 10:54:15 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Joint Venture Partner Receives $7.28 Million USD From Korean Government And Venture Fund For U.S. Development Of RGN-259/GBT-201 3/9/2015 7:09:48 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Israeli Patent For Treating And Repairing Heart Damage 2/25/2015 9:15:55 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Updates Website 2/19/2015 11:49:17 AM
12345678910...
//-->